Lobbying

Five things for pharma marketers to know: Tuesday, April 11, 2017

Five things for pharma marketers to know: Tuesday, April 11, 2017

By

Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer

Five things for pharma marketers to know: Thursday, October 27, 2016

Five things for pharma marketers to know: Thursday, October 27, 2016

By

BIO released a video explaining drug costs; the FDA commits to shorter generic approval process; Kaléo to launch EpiPen competitor

Five things for pharma marketers to know: Friday, July 15, 2016

Five things for pharma marketers to know: Friday, July 15, 2016

By

PhRMA brings on new members, Amgen partners with Daiichi Sankyo on biosimilar commercialization in Japan; Thomson Reuters to sell science unit

Five things for pharma marketers to know: Friday, March 4, 2016

Five things for pharma marketers to know: Friday, March 4, 2016

By

New PhRMA CEO issues policy strategy; study assess patient response to immuno-oncology drugs; Twitter may be an effective way to talk about clinical trials

Five things for pharma marketers to know: Monday, February 8, 2016

Five things for pharma marketers to know: Monday, February 8, 2016

PhRMA and BIO ramp up ad spend for presidential election year; Super Bowl Sunday features three pharma ads; Pfizer solidifies leadership team

Five things for pharma marketers to know: Monday, September 28, 2015

Five things for pharma marketers to know: Monday, September 28, 2015

By

PhRMA hires Ubl as CEO; two drugs report superior results in kidney-cancer trials compared to the standard of care; Novo Nordisk's shares rise on Tresiba approval

Five things for pharma marketers to know: Tuesday, July 21

Five things for pharma marketers to know: Tuesday, July 21

By

Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter

Five things for pharma marketers to know: Friday, April 17

Five things for pharma marketers to know: Friday, April 17

By

The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Who Needs a Gold Watch, Anyway?

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.